Hematology (all articles)
Single-arm P1/2 study | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma.
11 Nov, 2022 | 13:05h | UTCIberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentaries on Twitter
In a phase I trial of the novel cereblon E3 ligase modulator iberdomide+dexamethasone in pts with RRMM, SAEs occurred in 53%, with one treatment-related death. The ORRs were 32% in the dose-escalation (n=90) & 26% in the dose-expansion (n=107) cohorts: https://t.co/rfRCUfCABb
— NatureRevClinOncol (@NatRevClinOncol) October 14, 2022
NEW research: iberdomide plus dexa was generally safe and showed meaningful clinical activity in heavily pretreated patients with multiple myeloma, including in disease that was refractory to immunomodulatory drugs in this ph 1-2 trial #mmsmhttps://t.co/x1ta31eKtk pic.twitter.com/2URVIoFIAi
— The Lancet Haematology (@TheLancetHaem) October 7, 2022
RCT | Intermediate-dose no better than low-dose LMWH in pregnant and post-partum women with previous thromboembolism.
10 Nov, 2022 | 14:12h | UTCIntermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial https://t.co/9zHeUIda7o
— Saskia Middeldorp (@MiddeldorpS) October 28, 2022
RCT | Prophylactic tranexamic acid did not decrease bleeding in patients with hematologic malignancy.
10 Nov, 2022 | 13:36h | UTCCommentary: Tranexamic Acid (TXA) Prophylaxis in Patients with Hematologic Malignancies – Physician’s Weekly
M-A | DOACs increase the risk of arterial thrombosis vs. Vitamin-K antagonists in antiphospholipid syndrome.
9 Nov, 2022 | 12:28h | UTCDirect Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials – Journal of the American College of Cardiology (link to abstract – $ for full-text)
RCT | Brentuximab Vedotin with chemotherapy in pediatric high-risk Hodgkin’s Lymphoma.
4 Nov, 2022 | 13:30h | UTCBrentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Cohort Study | Prognostic value of FLT3-internal tandem duplication residual disease in AML.
3 Nov, 2022 | 13:36h | UTC
Observational study suggests Apixaban for AF is associated with a lower risk of GI bleeding vs. other DOACs.
3 Nov, 2022 | 13:32h | UTCComparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Best blood thinner for minimizing bleeding risk identified – University College London
Commentary: GI Bleeding Lower With Apixaban Versus Other DOACs in A-Fib – HealthDay
Dose-reduced direct oral anticoagulants: practical considerations.
31 Oct, 2022 | 13:52h | UTC
Post-trial follow-up | Updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
31 Oct, 2022 | 13:36h | UTC
Commentary on Twitter
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab https://t.co/hw7Tp9yjdu pic.twitter.com/CqMu2cMqRc
— Blood Journal (@BloodJournal) August 31, 2022
RCT | Sutimlimab in patients with cold agglutinin disease without recent transfusion.
31 Oct, 2022 | 13:37h | UTCEditorial: A virtuosic CADENZA played by sutimlimab – Blood
Commentary: Sutimlimab Shows Efficacy in Patients With CAD Without Recent Transfusion – AJMC
Commentary on Twitter
Read #openaccess article ‘Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial’ recently published in @BloodJournalhttps://t.co/K13e9V1c0K @ASH_Hematology pic.twitter.com/61oqWewcJ2
— Elsevier Hematology (@ELShematology) September 12, 2022
Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.
31 Oct, 2022 | 13:34h | UTCCommentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition
Review | Iron deficiency and cardiovascular disease.
27 Oct, 2022 | 12:31h | UTCIron deficiency and cardiovascular disease – European Heart Journal
Commentary on Twitter
#Iron deficiency and #cardiovascular disease. Great review in @ESC_Journals #CardioTwitter
📎 https://t.co/339s3LpPmk pic.twitter.com/0wHNHc6xEg
— Enrique Santas (@SantasEnrique) October 26, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Recommendations for laboratory testing of patients with acute myeloid leukemia.
25 Oct, 2022 | 13:21h | UTC
Systematic Review | Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
21 Oct, 2022 | 12:47h | UTC
Guideline | Diagnosis and management of febrile neutropenia in patients with cancer.
18 Oct, 2022 | 12:52h | UTCRelated:
Guidance | Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology.
13 Oct, 2022 | 13:46h | UTC
Cohort Study | Cardiovascular morbidity in monoclonal gammopathy of undetermined significance.
13 Oct, 2022 | 13:34h | UTC
Guideline | Evaluation and management of venous thromboembolism.
12 Oct, 2022 | 13:55h | UTCJoint Guideline on Venous Thromboembolism – 2022 – Arquivos Brasileiros de Cardiologia
Review | Point of care coagulation management in anesthesiology and critical care.
7 Oct, 2022 | 14:06h | UTCPoint of care coagulation management in anesthesiology and critical care – Minerva Anestesiologica
Phase 1 study | GPRC5D-Targeted CAR T Cells for patients with heavily pretreated Multiple Myeloma.
29 Sep, 2022 | 13:25h | UTCGPRC5D-Targeted CAR T Cells for Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Review | Direct-acting oral anticoagulant prescriptions in the emergency department.
27 Sep, 2022 | 13:08h | UTCDirect-Acting Oral Anticoagulant Prescriptions in the ED – emDocs
Platelet dysfunction after trauma: from mechanisms to targeted treatment.
26 Sep, 2022 | 11:56h | UTCPlatelet dysfunction after trauma: From mechanisms to targeted treatment – Transfusion
Effects of tranexamic acid treatment in severely and non-severely injured trauma patients.
26 Sep, 2022 | 11:54h | UTC
Guideline | Anemia management in surgical patients.
23 Sep, 2022 | 13:11h | UTC
Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.
23 Sep, 2022 | 13:07h | UTC
Commentary on Twitter
Chimeric antigen receptor T cells have revolutionised the treatment of hematological malignancies.
What practical aspects of a patient’s journey through this treatment should clinicians know about and what are current best practices to manage toxicities?https://t.co/idlA2Lv9uR
— The BMJ (@bmj_latest) September 4, 2022